PSMD11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1478606	0.58	12/20
SCHEMBL607010	0.56	12/20
SCHEMBL608381	0.53	12/20
SCHEMBL606616	0.51	12/20
SCHEMBL1477637	0.57	11/20
SCHEMBL607972	0.55	11/20
SCHEMBL608782	0.54	11/20
SCHEMBL609278	0.54	11/20
SCHEMBL607553	0.54	11/20
SCHEMBL605822	0.54	11/20
SCHEMBL606932	0.53	11/20
SCHEMBL1477893	0.53	11/20
SCHEMBL608362	0.53	11/20
SCHEMBL608599	0.53	11/20
SCHEMBL1327441	0.53	11/20
SCHEMBL605129	0.52	11/20
SCHEMBL608009	0.52	11/20
SCHEMBL1478157	0.52	11/20
SCHEMBL609081	0.52	11/20
SCHEMBL606926	0.52	11/20

Clinical trials — most relevant to PSMD11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease	PHASE4	UNKNOWN
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma	PHASE2	WITHDRAWN
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors	PHASE2	COMPLETED
Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma	PHASE2	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM	PHASE1	WITHDRAWN
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	PHASE1	COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma	PHASE1	COMPLETED
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma	PHASE1	COMPLETED
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment	nan	UNKNOWN
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk	nan	NOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Effect of Diaphragm Stimulation During Surgery	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Cardiovascular Complications of Carfilzomib Treatment	nan	UNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease	nan	COMPLETED
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve	nan	UNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMD11 binder may also engage these)

Protein	Name	Similarity
Q8BG32	—	1.000	Q8BG32 →
F1LMZ8	—	1.000	F1LMZ8 →
Q2KI42	—	1.000	Q2KI42 →
F6XBL2	—	1.000	F6XBL2 →
F6P3G4	—	0.994	F6P3G4 →
F1QGH9	—	0.990	F1QGH9 →
Q5R648	—	0.984	Q5R648 →
O88544	—	0.983	O88544 →
Q3SZA0	—	0.982	Q3SZA0 →
Q4R5E6	—	0.979	Q4R5E6 →
A7Y521	—	0.979	A7Y521 →
COPS4	COP9 signalosome complex subunit 4	0.978	landscape →
Q68FS2	—	0.978	Q68FS2 →
Q6P0H6	—	0.974	Q6P0H6 →
Q94899	—	0.969	Q94899 →
PSMD13	26S proteasome non-ATPase regulatory subunit 13	0.966	landscape →
Q5E964	—	0.965	Q5E964 →
GPS1	COP9 signalosome complex subunit 1	0.965	landscape →
Q6NRT5	—	0.963	Q6NRT5 →
P84169	—	0.960	P84169 →
B0BN93	—	0.959	B0BN93 →
Q2KJ46	—	0.958	Q2KJ46 →
Q9WVJ2	—	0.958	Q9WVJ2 →
AP2A2	AP-2 complex subunit alpha-2	0.958	landscape →
Q99LD4	—	0.957	Q99LD4 →
PSMD3	26S proteasome non-ATPase regulatory subunit 3	0.957	landscape →
P17427	—	0.954	P17427 →
P97834	—	0.954	P97834 →
P18484	—	0.953	P18484 →
P14685	—	0.953	P14685 →